Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Inito, a startup that helps women quickly track fertility hormones at home, raises $6M

From TechCrunch

By Aisha Malik

November 15, 2023

Inito, a startup that helps women quickly track fertility hormones at home, raises $6M

Inito, a YC alum that helps women track fertility hormones quickly at home, has raised $6 million in Series A funding led by Fireside Ventures. The startup’s fertility monitor and kit is designed to give users easy-to-read fertility diagnostic results directly on their phone in just 10 minutes. The Bengaluru, India-based startup was founded in […]

© 2023 TechCrunch. All rights reserved. For personal use only.

Most Recent

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

AI infrastructure company Infinity announced Monday a $15 million raise at a $100 million valuation from investors including Touring Capital, Principal VC, and researchers from companies such as OpenAI and Anthropic.

Jul 20, 2026

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

For the first time since 2024, StrictlyVC is coming back to New York City — and we're bringing the kind of access you’d expect from an under-wraps event to the whole startup, VC, and dealmaking community.

Jul 20, 2026

Neil Rimer thinks the AI money is coming back out

Neil Rimer thinks the AI money is coming back out

Neil Rimer, the venture capitalist who co-founded Index Ventures, predicts the historic wealth AI is generating in Silicon Valley will have to be redistributed, voluntarily or involuntarily.

Jul 17, 2026

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks has remade its image into an AI company and has published research on the cost savings of open-weight AI models for coding.

Jul 17, 2026

Similar Posts

Oova grabs another $10.3M, unveils membership model for at-home fertility testing

Oova grabs another $10.3M, unveils membership model for at-home fertility testing

Oova's new membership offering is priced at $99 and includes The Oova Kit, personalized support from healthcare professionals and access to a community of peers.

Jun 12, 2023

Mira is helping fill the hormone knowledge gap for women and the medical industry

Mira is helping fill the hormone knowledge gap for women and the medical industry

Hormones play a massive role in when and how easily women can get pregnant, but research and resources in this area are lacking. Mira is looking to change that. Mira is an at-home, palm-sized hormone testing device women use to test their urine for their hormone levels. Mira’s corresponding app deciphers their results and spots patterns which help women better plan for the right time to try to get pregnant or know when it’s time to bring up potential issues with their doctor. Sylvia Kang, the c

Sep 10, 2024

Tory Burch Foundation launches tool to help women founders find capital

Tory Burch Foundation launches tool to help women founders find capital

The tool comes at a perilous time for many women founders: last year, companies founded solely by women received just 1.9% of all capital allocated to US startups.

Mar 28, 2023

Herself Health, providing primary care to women 65 and over, raises $26M

Herself Health, providing primary care to women 65 and over, raises $26M

Six months after raising a $7 million seed round, Herself Health is back with some additional venture capital to expand its clinic footprint.

Jul 17, 2023

Most Recent

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

AI infrastructure company Infinity announced Monday a $15 million raise at a $100 million valuation from investors including Touring Capital, Principal VC, and researchers from companies such as OpenAI and Anthropic.

Jul 20, 2026

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

For the first time since 2024, StrictlyVC is coming back to New York City — and we're bringing the kind of access you’d expect from an under-wraps event to the whole startup, VC, and dealmaking community.

Jul 20, 2026

Neil Rimer thinks the AI money is coming back out

Neil Rimer thinks the AI money is coming back out

Neil Rimer, the venture capitalist who co-founded Index Ventures, predicts the historic wealth AI is generating in Silicon Valley will have to be redistributed, voluntarily or involuntarily.

Jul 17, 2026

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks has remade its image into an AI company and has published research on the cost savings of open-weight AI models for coding.

Jul 17, 2026

Similar Posts

Oova grabs another $10.3M, unveils membership model for at-home fertility testing

Oova grabs another $10.3M, unveils membership model for at-home fertility testing

Oova's new membership offering is priced at $99 and includes The Oova Kit, personalized support from healthcare professionals and access to a community of peers.

Jun 12, 2023

Mira is helping fill the hormone knowledge gap for women and the medical industry

Mira is helping fill the hormone knowledge gap for women and the medical industry

Hormones play a massive role in when and how easily women can get pregnant, but research and resources in this area are lacking. Mira is looking to change that. Mira is an at-home, palm-sized hormone testing device women use to test their urine for their hormone levels. Mira’s corresponding app deciphers their results and spots patterns which help women better plan for the right time to try to get pregnant or know when it’s time to bring up potential issues with their doctor. Sylvia Kang, the c

Sep 10, 2024

Tory Burch Foundation launches tool to help women founders find capital

Tory Burch Foundation launches tool to help women founders find capital

The tool comes at a perilous time for many women founders: last year, companies founded solely by women received just 1.9% of all capital allocated to US startups.

Mar 28, 2023

Herself Health, providing primary care to women 65 and over, raises $26M

Herself Health, providing primary care to women 65 and over, raises $26M

Six months after raising a $7 million seed round, Herself Health is back with some additional venture capital to expand its clinic footprint.

Jul 17, 2023